Matsunaga Mototsugu, Miwa Keisuke, Oka Yosuke, Nagasu Sachiko, Sakaue Takahiko, Fukahori Masaru, Ushijima Tomoyuki, Akagi Yoshito
Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.
Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan.
Case Rep Oncol. 2016 Apr 29;9(1):280-4. doi: 10.1159/000446066. eCollection 2016 Jan-Apr.
Because of their rarity, there are no clear guidelines for the treatment of anal carcinomas; such tumors are normally subjected to the same modalities as recommended for rectal cancer. We report a patient with anal canal mucinous adenocarcinoma, with metastases in the pararectal and right inguinal lymph nodes, who was treated with abdominoperineal resection followed by mFOLFOX6 chemotherapy for 6 months (12 cycles). The patient has remained recurrence-free thus far, approximately 2 years since the surgery. As the optimal treatments for anal carcinomas have not been fully elucidated, we present this case to highlight a possible course of action for such patients that appears to be effective and promising.
由于肛管癌较为罕见，目前尚无明确的治疗指南；此类肿瘤通常采用与直肠癌相同的治疗方式。我们报告一例肛管黏液腺癌患者，其直肠旁和右侧腹股沟淋巴结有转移，接受了腹会阴联合切除术，随后接受mFOLFOX6化疗6个月（12个周期）。自手术以来约2年，该患者至今未复发。由于肛管癌的最佳治疗方法尚未完全阐明，我们呈现此病例以突出一种对此类患者可能有效的、有前景的治疗方案。
